Anti-tumor therapy strategy of CAR-T cells based on stem cell memory and central memory cells.
- Author:
Weihua LIU
1
;
Yifei WANG
2
;
Xiaoting SUN
1
;
Zhibin WANG
3
Author Information
1. Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Chinese Academy of Sciences, Shenzhen 518055, China.
2. Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Chinese Academy of Sciences, Shenzhen 518055; University of Chinese Academy of Sciences, Beijing 101408, China.
3. Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Chinese Academy of Sciences, Shenzhen 518055; University of Chinese Academy of Sciences, Beijing 101408; Laboratory of Human Environmental Epigenomes, Department of Biopharmaceutical Sciences, School of Pharmaceutical Science, Shenzhen University of Advanced Technology, Shenzhen 518107, China.*Corresponding author, E-mail: zb.wang@siat.ac.cn.
- Publication Type:English Abstract
- MeSH:
Humans;
Immunotherapy, Adoptive/methods*;
Receptors, Chimeric Antigen/genetics*;
Neoplasms/immunology*;
Immunologic Memory;
T-Lymphocytes/immunology*;
Memory T Cells/immunology*;
Animals;
Stem Cells/cytology*;
Cell Differentiation
- From:
Chinese Journal of Cellular and Molecular Immunology
2024;40(12):1121-1126
- CountryChina
- Language:Chinese
-
Abstract:
Cancer immunotherapy including immune checkpoint inhibitors and adoptive cell therapy has gained revolutionary success in the treatment of hematologic tumors; however, it only gains limited success in solid tumors. For example, chimeric antigen receptor T (CAR-T) cell therapy has shown significant effects and potential for curing patients with B-cell malignancies. In contrast, it remains a challenge for CAR-T cell therapy to gain similar success in solid tumors. The anti-tumor effect of endogenous or adoptively transferred tumor-specific T cells depends largely on their differentiation status. T cells at early differentiation stage show better anti-tumor therapeutic effects than fully differentiated effector T cells. In cancer patients, the persistence of tumor-specific T cells with the stem cell memory or precursor phenotype is significantly associated with improved therapeutic outcomes; therefore, adoptively transfered CAR-T cells with stem cell memory and/or central memory is expected to gain better anti-tumor effects. Herein we focused on the in vitro optimized culture and expansion system to obtain CAR-T cells with stem cell memory or central memory phenotype for the review.
